10th IAS Conference on HIV Science (IAS 2019) in Mexico City

23 August 2019. Related: Conference reports, Conference index, IAS 10 Mexico City 2019.

Simon Collins, HIV i-Base

The 10th IAS Conference on HIV Science (IAS 2019) in Mexico City was held from 21 – 24 July 2019.

The programme is posted online, with abstracts and PowerPoint slides available for many of the presentations.

http://www.ias2019.org

Reports in the last issues of HTB focused on:

• New antiretroviral drugs.
• ART strategies with new and existing drugs.
• An important (and optimistic) update on neural tube defects with dolutegravir, with a comprehensive review of the latest data.
• Updates to WHO treatment guidelines

HTB reports in this issue include:

• Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

• Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

• Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

• PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study